Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02212561
Recruitment Status : Completed
First Posted : August 8, 2014
Last Update Posted : March 3, 2017
Karyopharm Therapeutics Inc
Information provided by (Responsible Party):
St. Jude Children's Research Hospital